Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.50 |
| ▸ | PYGM | P11217 | 1/20 | 0.49 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378594 | 0.85 | ALB (0.53) | PLA2G7HRH4MEN1KMT2ARCE1 | |
| SCHEMBL17149718 | 0.85 | ALB (0.53) | PLA2G7HRH4MEN1KMT2ARCE1 | |
| SCHEMBL17149696 | 0.85 | ALB (0.53) | PLA2G7HRH4MEN1KMT2ARCE1 | |
| SCHEMBL17149719 | 0.81 | HRH4 (0.49) | PYGLPYGMHRH4NPC1 | |
| SCHEMBL17149617 | 0.80 | PYGL (0.63) | PYGLMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL17149903 | 0.80 | PYGL (0.63) | PYGLMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL17149864 | 0.80 | PYGL (0.63) | PYGLMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL17149721 | 0.79 | MEN1 (0.52) | PYGLMEN1KMT2ARCE1NPC1 | |
| SCHEMBL17149856 | 0.78 | KMT2A (0.50) | HRH4MEN1KMT2ARCE1PDE2A | |
| SCHEMBL17149911 | 0.77 | ALOX15 (0.72) | PYGLMEN1KMT2ARCE1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | PYGL 60/4885PYGM 576/4885PLA2G7 2315/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | PYGL 63/4885PYGM 574/4885PLA2G7 2232/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | PYGL 63/4885PYGM 574/4885PLA2G7 2232/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | PYGL 65/4885PYGM 642/4885PLA2G7 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.